Financing Autism and Developmental Services Beyond Health Insurance
How a Federal Benefit Could Preserve Access, Improve Oversight, and Modestly Reduce Premiums
Abstract: State insurance mandates and Medicaid requirements have expanded access to autism and developmental therapies but have also placed substantial recurring costs on commercial insurance pools and state Medicaid programs. This memorandum proposes a dedicated federal benefit to finance qualifying developmental services while establishing national standards for eligibility, medical necessity, provider qualifications, treatment review, and program integrity. Moving these services outside conventional health insurance would reduce claims paid by commercial insurers and could therefore modestly reduce premiums and Affordable Care Act premium subsidies. Those savings would partially offset the cost of the new federal benefit, although the net fiscal effect and the size of any premium reduction would require formal actuarial analysis.
The line between medical care and social development has blurred. Historically, health insurance excluded non-medical behavioral therapies, leaving them to schools and families. Today, state and federal mandates require commercial plans and Medicaid to cover long-term behavioral interventions like Applied Behavior Analysis (ABA). While these mandates have largely survived broader federal budget cuts to Medicaid and private insurance, they significantly increase health insurance premiums. Transitioning to a new federal program that pays for developmental and autism treatments outside the traditional health insurance infrastructure would modestly decrease premiums and reduce the overall number of uninsured Americans.
The growth in insurance mandates for developmental services has triggered substantive fiscal strain. A prominent Wall Street Journal investigation, “The Boom in Autism Therapy Is Medicaid’s Largest Jackpot,” revealed that Indiana’s Medicaid program paid a single provider $29 million in one year to treat just 84 children—roughly $340,000 per child. This far exceeds the annual cost of treating a lung cancer patient. Similarly, federal audits found that Colorado spent more Medicaid funds on pediatric autism therapy than on emergency room care for all patients combined, documenting widespread billing for napping, eating, and playing video games.
The push for mandatory coverage began in the mid-2000s, driven by rising autism diagnoses and aggressive lobbying by advocacy groups like Autism Speaks. Between 2007 and 2019, these campaigns successfully established insurance mandates across all 50 states, applying heavily to employer-based and state exchange insurance. The Affordable Care Act (ACA) further reinforced these requirements by classifying autism treatment as an Essential Health Benefit (EHB) in many states.
In contrast, most large corporate employer-based plans are “self-insured”—covering roughly 57% to 60% of all insured American workers. Under these arrangements, the company pays medical claims directly out of its own pocket, utilizing a standard commercial carrier only for administrative services. Under federal law, these plans are governed strictly by the Employee Retirement Income Security Act (ERISA), which entirely exempts them from state-level insurance mandates.
Driven in part by federal mental health parity compliance and the safety net of stop-loss reinsurance, a growing number of large enterprises still choose to offer these benefits voluntarily. Historical data from Autism Speaks notes that roughly 45% of companies with 500 or more employees explicitly opt to include ABA or intensive behavioral therapies within their self-funded plan designs.
However, because an intensive, 40-hour-a-week ABA regimen introduces significant financial volatility, most mid-to-large, self-insured employers do not take on this risk entirely exposed. Instead, they purchase stop-loss insurance (a form of private reinsurance) to transfer liability to a secondary carrier once an individual child’s annual therapy claims clear a specific “attachment point” or deductible—which typically ranges from $70,000 to over $300,000 depending on firm size.
Politically, autism mandates have proven to be exceptionally resilient, creating a sharp paradox within conservative healthcare policy. For example, the Trump administration issued sweeping regulations modifying the ACA’s EHB framework via the 2019 Notice of Benefit and Payment Parameters. This rule granted states unprecedented flexibility to choose new benchmark plans or swap out entire benefit categories to lower costs. Yet, notably, this regulatory mechanism was never applied to this specific clinical group.
Similarly, the administration’s sweeping Medicaid overhauls—anchored by aggressive fiscal tightening, state budget caps, and strict work requirements—deliberately avoided targeting autism benefits. Despite pushing for massive Medicaid spending reductions, federal reforms left the Early and Periodic Screening, Diagnostic and Treatment (EPSDT) mandate completely intact.
Because EPSDT legally compels states to provide any “medically necessary” treatment to low-income children under 21, pediatric ABA therapy survived federal budget battles entirely unscathed. While states under pressure from fiscal caps may scale back optional adult dental or vision benefits, the statutory framework protecting pediatric behavioral health remains virtually impossible to roll back without triggering insurmountable legal risks.
Because intensive behavioral therapies frequently require up to 40 hours a week per child, they create an expensive, continuous drain on standard commercial insurance pools. Small businesses purchasing group coverage and individuals buying policies on state exchanges end up subsidizing these long-term developmental services through higher monthly premiums.
Extracting these developmental services from the standard commercial insurance framework entirely—and transitioning them to an independent, standalone federal program—would correct these distorted insurance mechanics. Rather than dropping or eliminating access to autism services, a structural pivot to a dedicated Federal Developmental Assistance Program would isolate the costs of long-term behavioral therapy from basic medical insurance pools.
A well-designed program could preserve access while vastly improving the financing and oversight of autism and developmental services. The framework would require:
Clear eligibility standards and a precise division between developmental services and ordinary medical care.
Strict coordination rules with Medicaid, EPSDT, state insurance mandates, and school-based services under the Individuals with Disabilities Education Act (IDEA).
National requirements for provider qualifications, standardized treatment plans, independent medical-necessity reviews, periodic recertification, and strict auditing to prevent fraud.
The enacting legislation would also need to determine whether the federal program serves as the primary payer or reimburses states, require insurers to legally reflect transferred claims costs in lower consumer premiums, and identify a sustainable financing mechanism that accounts for offsetting reductions in Medicaid spending and ACA premium subsidies. With these protections, the reform could broaden the financing base, strengthen program integrity, and modestly reduce commercial insurance premiums without withdrawing needed assistance from families.
This policy shift would immediately drop commercial premiums. For a typical 40-year-old couple with two children purchasing an unsubsidized silver plan on a state exchange (costing roughly $1,800 a month), a modest 1% to 3% rate reduction would save that household $18 to $55 a month, translating to $216 to $660 in annual savings.
From a macroeconomic perspective, establishing a separate federal developmental program would reallocate public capital without drastically altering total national healthcare spending as a share of GDP. While a new federal program represents a new spending line item, it would yield a non-trivial decrease in private health insurance premiums and federal premium subsidies. While not a complete transformation of American medicine, the resulting premium drop would modestly reduce the number of uninsured Americans, moving national healthcare policy in a more sustainable direction.